Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amphotericin B · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | - |
| Amphotericin B | DRUG | - |
Inclusion Criteria Patients must have: * HIV positive or negative status. * Blastomycosis or histoplasmosis. * Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Liver disease. * Self-limiting fungal ...
Top 20 of 28 competitors
Amphotericin B is an investigational small molecule being studied for the treatment of HIV infections, specifically in patients with histoplasmosis or blastomycosis. It is currently in Phase 3 clinical development and has completed one trial with 60 participants.
Amphotericin B is a small molecule antifungal agent. It works by binding to ergosterol, a component of fungal cell membranes, forming pores that lead to cell death. This mechanism is relevant for treating fungal infections in HIV patients.
Amphotericin B is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 3 clinical trials for infectious disease indications.
Amphotericin B is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is not currently in active trials.
Amphotericin B has been studied in one completed Phase 3 trial, NCT00002159. This open-label, uncontrolled study compared initial treatment with intravenous itraconazole versus Amphotericin B followed by consolidation with itraconazole capsules in patients with blastomycosis or histoplasmosis and HIV infections.
No, Amphotericin B is not the same as itraconazole. They are different antifungal drugs. In the clinical trial NCT00002159, Amphotericin B was compared against itraconazole as an initial treatment, and patients receiving Amphotericin B were later switched to itraconazole for consolidation therapy.